1 Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39:2214–29.
2 Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
3 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.
4 Goossens N, Toso C, Heim MH. Management of hepatocellular carcinoma: SASL expert opinion statement. Swiss Med Wkly. 2020;150:w20296.
5 Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology. 2018;154:1706–18.
6 Biselli M, Conti F, Gramenzi A, Frigerio M, Cucchetti A, Fatti G, et al. A new approach to the use of α-fetoprotein as surveillance test for hepato-cellular carcinoma in patients with cirrhosis. Br J Cancer. 2015;112:69–76.
7 Lersritwimanmaen P, Nimanong S. Hepatocellular Carcinoma Surveillance: Benefit of Serum Alfa-fetoprotein in Real-world Practice. Euroasian J Hepatogastroenterol. 2018;8(1):83–7.
8 Tayob N, Lok ASF, Do KA, Feng Z. Improved Detection of Hepatocellular Carci-noma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. lin Gastroenterol Hepatol. 2016;14(3):469–75.e2.